australian brain cancer market

Australian Brain Cancer Market: Segmented by Therapy Type (Radiation Therapy, Chemotherapy, Targeted Therapy, Surgery, Immunotherapy, & Others), by Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, & Others)- Growth, Trends, and Forecasts (2019 2028)

  • Published Date: 2022-12-28
  • Report ID: 139957
  • Pages: 200
  • Format: prudent report format

Report Overview

The Australian Brain Cancer market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Brain cancers include primary brain tumors, which start in the brain and almost never spread to other parts of the body, and secondary tumors (or metastases), which are caused by cancers that began in another part of the body. There are more than 40 major types of brain tumors, which are grouped into two main types they are benign and malignant. A brain tumor may be a primary or secondary cancer. Cancer that first develops in the brain is called primary brain cancer. It rarely spreads to other parts of the body but may spread to other parts of the brain. Sometimes cancer starts in another part of the body and then travels through the bloodstream to the brain. This is known as secondary cancer or metastasis. Every year an estimated 2000 malignant brain tumors are diagnosed in Australia. Malignant spinal cord tumors are rare. About 55 people are diagnosed with malignant spinal cord or other central nervous system tumors each year.



Market Drivers

The market size drivers for the growth of brain cancer diagnostics are expected to propel by technological developments, improvements in diagnostics machines. The rise in the number of cigarette smokers responsible for brain cancer has contributed to the market size.

In 2019, the NDSHS reported current smokers aged 18 and over smoked an average of 12.9 cigarettes per day. Men and women smoked a similar number of cigarettes per day in 2019an average of 13.1 and 12.9 cigarettes per day, respectively.

The population above 60 years of age forms the target demographic segment for this vertical, as this population subset is more prone to neurological conditions. The advancement of diagnostics equipment increases the lifespan of this demographic and improves the quality of life for those suffering from neurological conditions. Hence, the presence of a large geriatric population pool is considered a vital driver for this industry.

Epidemiology

In 2016, there were 1,771 new cases of brain cancer diagnosed in Australia (1,062 males and 709 females). In 2020, it is estimated that 1,879 new cases of brain cancer will be diagnosed in Australia (1,113 males and 767 females).

In 2018, there were 1,410 deaths from brain cancer in Australia (845 males and 565 females). In 2020, it is estimated that there will be 1,518 deaths (921 males and 597 females).

In 20122016, individuals diagnosed with brain cancer had a 22 % chance (21% for males and 24% for females) of surviving for five years compared to their counterparts in the general Australian population.

At the end of 2015, there were 1,317 people living who had been diagnosed with brain cancer that year, 3,279 people living who had been diagnosed with brain cancer in the previous 5 years.


1. Australian Brain Cancer Market Overview...........................
A. Market Size
2. Market Growth Drivers..
A. Rise in Prevalence of Brain Cancer
B. Rise in the Number of Cigarette Smokers
C. Increase in Geriatric Population
3. Epidemiology.
A. New cases
B. Deaths & Survival
C. Prevalence
4. Brain Cancer Market Segmentation........................
A. Therapy Type
I. Radiation Therapy
II. Chemotherapy
III. Targeted Therapy
IV. Surgery
V. Immunotherapy
VI. Others
B. Distribution
I. Hospital Pharmacies
II. Retail Pharmacies
III. Online Pharmacies
IV. Others
5. Brain Cancer Major Products Market Share.
A. Market Analysis, Insights and Forecast By Revenue
6. Competitive Landscape......
A. Major Players
B. Products in Pipeline
7. Key Company Profiles.
A. F. Hoffmann-La Roche Diagnostics overview, Product & Services, Strategies & Financials
B. AstraZeneca overview, Product & Services, Strategies & Financials
C. Pfizer overview, Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape
A. Policy changes and Reimbursement scenario
9. Factors Driving Future Growth
A. New Trends and Development of Brain Cancer Market
B. Future Opportunities
10. Conclusion
CHOOSE LICENCE TYPE
prudent payment methods
Contact Us

Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071

Drop us an email at
sales@prudentmarkets.com

Why Choose Us
24 * 7 Access to Analyst :

Get your pre and post sales queries resolved by our Subject matter experts.

Customization :

We will assist you to customize the report to fit your research needs.

Assured Quality :

Our prime focus is to provide qualitative and accurate data.

Free sample report :

Feel free to order a sample report before purchase.

Security :

Your personal and confidential information is safe and secured.